NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04877522 2026-03-06
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04626024 2025-12-19
TOKIN
Baylor College of Medicine
Phase 2 Recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT04835584 2022-03-21
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
Phase 1/2 Recruiting